Literature DB >> 25490188

Equilibrium contrast-enhanced CT imaging to evaluate hepatic fibrosis: initial validation by comparison with histopathologic sampling.

Steve Bandula1, Shonit Punwani, William M Rosenberg, Rajiv Jalan, Andrew R Hall, Amar Dhillon, James C Moon, Stuart A Taylor.   

Abstract

PURPOSE: To prospectively evaluate hepatic extracellular volume (ECV) fraction measurement at equilibrium computed tomographic (CT) imaging compared with both fibrosis quantified with histologic analysis and the enhanced liver fibrosis panel (ELF) in a cohort of patients with chronic hepatitis.
MATERIALS AND METHODS: This prospective study was approved by the regional ethics committee. All patients gave fully informed written consent. Forty patients with a clinical indication for liver biopsy were prospectively recruited for liver ECV quantitation at equilibrium CT imaging. Biopsy samples underwent digital image analysis and assessment of collagen content expressed as the collagen-proportionate area (CPA). Spearman correlation was used to evaluate association between ECV, ELF, and CPA. Multiple regression analysis was used to test prediction of CPA by a model that combined ECV and ELF. ECV, ELF score, and CPA were compared with Ishak stage by using the Kruskal-Wallis test.
RESULTS: Complete ECV, ELF, and CPA were available in 33 patients. Liver ECV, CPA, and ELF had a median of 0.26 (interquartile range [IQR], 0.24-0.29), 5.0 (IQR, 3.0-15.0), and 9.71 (IQR, 8.14-10.92), respectively. Hepatic ECV demonstrated good association with CPA (r = 0.64; P < .001) and ELF score (r = 0.38; P < .027), with no significant difference in strength of correlation (P = .177). The regression model that combined ELF and ECV achieved good prediction of CPA (R(2) = 0.67; P < .001). Significant variation in ECV and ELF was seen between fibrosis stage groups.
CONCLUSION: Hepatic ECV measured with equilibrium CT imaging is associated with biopsy-derived CPA and serum ELF-validated markers of liver fibrosis. This suggests that equilibrium CT imaging can quantify diffuse fibrosis in chronic liver disease.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25490188     DOI: 10.1148/radiol.14141435

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  17 in total

1.  Dual-energy CT quantification of fractional extracellular space in cirrhotic patients: comparison between early and delayed equilibrium phases and correlation with oesophageal varices.

Authors:  Giuseppe Cicero; Silvio Mazziotti; Salvatore Silipigni; Alfredo Blandino; Vito Cantisani; Stefano Pergolizzi; Tommaso D'Angelo; Alberto Stagno; Sergio Maimone; Giovanni Squadrito; Giorgio Ascenti
Journal:  Radiol Med       Date:  2021-03-14       Impact factor: 3.469

2.  Feasibility of computed tomography texture analysis of hepatic fibrosis using dual-energy spectral detector computed tomography.

Authors:  ByukGyung Choi; In Young Choi; Sang Hoon Cha; Suk Keu Yeom; Hwan Hoon Chung; Seung Hwa Lee; Jaehyung Cha; Ju-Han Lee
Journal:  Jpn J Radiol       Date:  2020-07-14       Impact factor: 2.374

Review 3.  Evaluation of hepatic fibrosis: a review from the society of abdominal radiology disease focus panel.

Authors:  Jeanne M Horowitz; Sudhakar K Venkatesh; Richard L Ehman; Kartik Jhaveri; Patrick Kamath; Michael A Ohliger; Anthony E Samir; Alvin C Silva; Bachir Taouli; Michael S Torbenson; Michael L Wells; Benjamin Yeh; Frank H Miller
Journal:  Abdom Radiol (NY)       Date:  2017-08

4.  Hepatosplenic volumetric assessment at MDCT for staging liver fibrosis.

Authors:  Perry J Pickhardt; Kyle Malecki; Oliver F Hunt; Claire Beaumont; John Kloke; Timothy J Ziemlewicz; Meghan G Lubner
Journal:  Eur Radiol       Date:  2016-11-17       Impact factor: 5.315

5.  Extracellular volume fraction determined by equilibrium contrast-enhanced multidetector computed tomography as a prognostic factor in unresectable pancreatic adenocarcinoma treated with chemotherapy.

Authors:  Yoshihiko Fukukura; Yuichi Kumagae; Ryutaro Higashi; Hiroto Hakamada; Koji Takumi; Kosei Maemura; Michiyo Higashi; Kiyohisa Kamimura; Masanori Nakajo; Takashi Yoshiura
Journal:  Eur Radiol       Date:  2018-06-19       Impact factor: 5.315

6.  Using T1 mapping in cardiovascular magnetic resonance to assess congestive hepatopathy.

Authors:  Isabel Kazour; Suraj D Serai; Stavra A Xanthakos; Robert J Fleck
Journal:  Abdom Radiol (NY)       Date:  2018-10

7.  Dual-source dual-energy CT in the evaluation of hepatic fractional extracellular space in cirrhosis.

Authors:  Antonio Bottari; Salvatore Silipigni; Maria Ludovica Carerj; Antonino Cattafi; Sergio Maimone; Maria Adele Marino; Silvio Mazziotti; Alessia Pitrone; Giovanni Squadrito; Giorgio Ascenti
Journal:  Radiol Med       Date:  2019-10-05       Impact factor: 3.469

Review 8.  Dual-energy CT in diffuse liver disease: is there a role?

Authors:  Khaled Y Elbanna; Bahar Mansoori; Achille Mileto; Patrik Rogalla; Luís S Guimarães
Journal:  Abdom Radiol (NY)       Date:  2020-08-08

9.  Correlation of hepatic fractional extracellular space using gadolinium enhanced MRI with liver stiffness using magnetic resonance elastography.

Authors:  Michael L Wells; Michael R Moynagh; Rickey E Carter; Robert A Childs; Cameron E Leitch; Joel G Fletcher; Benjamin M Yeh; Sudhakar K Venkatesh
Journal:  Abdom Radiol (NY)       Date:  2017-01

10.  CT texture analysis of the liver for assessing hepatic fibrosis in patients with hepatitis C virus.

Authors:  Meghan G Lubner; Daniel Jones; John Kloke; Adnan Said; Perry J Pickhardt
Journal:  Br J Radiol       Date:  2018-10-11       Impact factor: 3.039

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.